27. Barlow PG, et al. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in
different primary cells of the innate immune system. J Leuko Biol. 2006(80):509–520.
28. Bowdish DM, Davidson DJ, Speert DP, Hancock RE. The human cationic peptide LL-37 induces activation of the extracellular
signal-regulated kinase and p38 kinase pathways in primary human monocytes. J Immunol. 2004(172):3758–3765.
29. Davidson DJ, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced
T-cell polarization. J Immunol. 2004(172):1146–1156.
30. De Y, et al. LL-37, the neutrophils granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like
1 (FPRL1) as a receptor to chemo-attract human peripheral blood neutrophils, monocytes, and T-cells. J Experim Med. 2000(192):1069–1074.
31. Lau, YE, Bowdish DM, Cosseau C, Hancock RE, Davidson DJ. Apoptosis of airway epithelial cells: Human serum sensitive
induction by the cathelicidin LL-37. Am J Respir Cell Mol Biol. 2006(34):399–409.
32. Mookherjee N, et al. Bovine and human cathelicidin cationic host defense peptides similarly suppress transcriptional
responses to bacterial lipopolysaccharide. J Leukoc Biol. 2006(80):1563–1574.
33. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial peptide LL-37 is a multifunctional modulator
of innate immune responses. J Immunol. (2002)169:3883–3891.
34. Scott MG, Rosenberger CM, Gold MR, Finlay BB, Hancock RE. An alpha-helical cationic antimicrobial peptide selectively
modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression. J Immunol. 2000(165):3358–3365.
35. Lillard JW Jr., Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by
neutrophils peptide defensins. Proc Natl Acad Sci USA. 1999(96):651–656.
36. Tani K,et al. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma
idiotype and carrier antigens. Int Immunol. 2000(12):691–700.
37. Brogden KA, et al. Defensin-induced adaptive immunity in mice and its potential in preventing periodontal disease. Oral
Microbiol Immunol. 2003(18):95–99.
38. Biragyn A, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002(298):1025–1029.
39. Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, Kwak LW. DNA vaccines encoding human immunodeficiency virus-1
glycoprotein 120 fusions with pro-inflammatory chemo-attractants induce systemic and mucosal immune responses. Blood. 2002(100):1153–1159.
40. Allcock HR. Polyphoshazenes as new biomedical and bioactive material. New York: Marcel Dekker;1990.
41. McNeal MM, Rae MN, Ward RL. Effects of different adjuvants on rotavirus antibody responses and protection in mice following
intramuscular immunization with inactivated rotavirus. Vaccine. 1999(17):1573–1580.
42. Payne LG, Andrianov AK. Protein release from polyphosphazene matrices. Adv Drug Deliv Rev. 1998(31):185–196.
43. Wu Y, Wang X, Csencsits KL, Haddad A, Walters N, Pascual DW. M cell-targeted DNA vaccination. Proc Natl Acad Sci USA.
44. Mutwiri G, Gerdts V, Lopez M, Babiuk LA. Innate immunity and new adjuvants. Rev Sci Tech Off Int Epiz. 2007(26):147–156.
45. Mutwiri G, et al. Poly[di(sodium carboxylatoethylphenoxy)phos-
phazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine